HEMODYNAMIC EFFECTS OF DOBUTAMINE & MILRINONE
多巴酚丁胺的血流动力学效应
基本信息
- 批准号:6425942
- 负责人:
- 金额:$ 0.16万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1998
- 资助国家:美国
- 起止时间:1998-12-01 至 1999-11-30
- 项目状态:已结题
- 来源:
- 关键词:beta antiadrenergic agent clinical research cyclic AMP dobutamine drug interactions drug screening /evaluation gene expression heart disorder chemotherapy heart failure hemodynamics human subject human therapy evaluation idiopathic dilated cardiomyopathy pharmacokinetics phosphodiesterase inhibitors
项目摘要
This is a randomized, double-blind, parallel group, active-controlled trial of eighteen months' duration and a total of 72 patients. The study will be performed at two sites, the University of Utah GCRC and the University of Colorado GCRC. Patients with NYHA class II-IV heart failure due to idiopathic dilated cardiomyopathy will be treated with either bucindolol or metoprolol to determine changes in myocardial gene expression associated with either of these drugs. Changes in gene expression associated with alterations in myocardial function and remodeling are also under study. If bucindolol or metoprolol proves to lower cardiac adrenergic drive, then the relationship of this effect to changes in myocardial gene expression will be defined. If bucindolol or metoprolol lowers activity of the renin-angiotensin system, then the relationship of this effect will also be correlated with changes in myocardial gene expression. Milrinone is a phosphodiesterase inhibitor and the use of this agent will enable the investigators to determine if the effects of bucindolol are enhanced by this drug, suggesting that bucindolol may also act through a cyclic-AMP-dependent mechanism. This study is in its earliest phases but no data are mature enough to report.
这是一项为期18个月的随机、双盲、平行组、活性对照试验,共纳入72例患者。 本研究将在两个研究中心(犹他州大学GCRC和科罗拉多大学GCRC)进行。 特发性扩张型心肌病导致NYHA II-IV级心力衰竭的患者将接受布新洛尔或美托洛尔治疗,以确定与这两种药物相关的心肌基因表达变化。 与心肌功能改变和重塑相关的基因表达变化也在研究中。 如果布新洛尔或美托洛尔被证明降低心脏肾上腺素能驱动,那么这种作用与心肌基因表达变化的关系将被确定。 如果布新洛尔或美托洛尔降低了肾素-血管紧张素系统的活性,那么这种作用的关系也将与心肌基因表达的变化相关。米力农是一种磷酸二酯酶抑制剂,使用这种药物将使研究人员能够确定布新洛尔的作用是否被这种药物增强,这表明布新洛尔也可能通过环AMP依赖性机制起作用。这项研究处于早期阶段,但没有足够成熟的数据可以报告。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
E MICHAEL GILBERT其他文献
E MICHAEL GILBERT的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('E MICHAEL GILBERT', 18)}}的其他基金
CHRONIC BETA-BLOCKER TREATMENT IN HEART FAILURE
心力衰竭的慢性 β 受体阻滞剂治疗
- 批准号:
7376447 - 财政年份:2006
- 资助金额:
$ 0.16万 - 项目类别:
CHRONIC BETA-BLOCKER TREATMENT IN HEART FAILURE
心力衰竭的慢性 β 受体阻滞剂治疗
- 批准号:
7201429 - 财政年份:2005
- 资助金额:
$ 0.16万 - 项目类别:
BETA BLOCKER EFFECT ON REMODELING AND GENE EXPRESSION (BORG)
β 受体阻滞剂对重塑和基因表达的影响 (BORG)
- 批准号:
7201422 - 财政年份:2005
- 资助金额:
$ 0.16万 - 项目类别:
Beta blocker effect on remodeling and gene expression (BORG)
β 受体阻滞剂对重塑和基因表达的影响 (BORG)
- 批准号:
7044777 - 财政年份:2004
- 资助金额:
$ 0.16万 - 项目类别:
相似海外基金
FAIRClinical: FAIR-ification of Supplementary Data to Support Clinical Research
FAIRClinical:补充数据的 FAIR 化以支持临床研究
- 批准号:
EP/Y036395/1 - 财政年份:2024
- 资助金额:
$ 0.16万 - 项目类别:
Research Grant
The IDeA State Consortium for a Clinical Research Resource Center: Increasing Clinical Trials in IDeA States through Communication of Opportunities, Effective Marketing, and WorkforceDevelopment
IDeA 州临床研究资源中心联盟:通过机会交流、有效营销和劳动力发展增加 IDeA 州的临床试验
- 批准号:
10715568 - 财政年份:2023
- 资助金额:
$ 0.16万 - 项目类别:
Optimizing integration of veterinary clinical research findings with human health systems to improve strategies for early detection and intervention
优化兽医临床研究结果与人类健康系统的整合,以改进早期检测和干预策略
- 批准号:
10764456 - 财政年份:2023
- 资助金额:
$ 0.16万 - 项目类别:
The Mayo Clinic NeuroNEXT Clinical Research Site
梅奥诊所 NeuroNEXT 临床研究网站
- 批准号:
10743328 - 财政年份:2023
- 资助金额:
$ 0.16万 - 项目类别:
Addressing Underperformance in Clinical Trial Enrollments: Development of a Clinical Trial Toolkit and Expansion of the Clinical Research Footprint
解决临床试验注册表现不佳的问题:开发临床试验工具包并扩大临床研究足迹
- 批准号:
10638813 - 财政年份:2023
- 资助金额:
$ 0.16万 - 项目类别:
Improving Multicultural Engagement in Clinical Research through Partnership with Federally Qualified Health Centers and Community Health Worker Programs
通过与联邦合格的健康中心和社区卫生工作者计划合作,改善临床研究中的多元文化参与
- 批准号:
10823828 - 财政年份:2023
- 资助金额:
$ 0.16万 - 项目类别:
The Minnesota TMD IMPACT Collaborative: Integrating Basic/Clinical Research Efforts and Training to Improve Clinical Care
明尼苏达州 TMD IMPACT 协作:整合基础/临床研究工作和培训以改善临床护理
- 批准号:
10828665 - 财政年份:2023
- 资助金额:
$ 0.16万 - 项目类别:
Promoting a Culture Of Innovation, Mentorship, Diversity and Opportunity in NCI Sponsored Clinical Research: NCI Research Specialist (Clinician Scientist) Award Application of Janice M. Mehnert, M.D.
在 NCI 资助的临床研究中促进创新、指导、多样性和机会文化:Janice M. Mehnert 医学博士的 NCI 研究专家(临床科学家)奖申请
- 批准号:
10721095 - 财政年份:2023
- 资助金额:
$ 0.16万 - 项目类别:
Clinical Research Center for REstoration of NEural-based Function in the Real World (RENEW)
现实世界神经功能恢复临床研究中心 (RENEW)
- 批准号:
10795328 - 财政年份:2023
- 资助金额:
$ 0.16万 - 项目类别:
Clinical Research and Academic Success in Obstetrics & Gynecology
产科临床研究和学术成就
- 批准号:
10828252 - 财政年份:2023
- 资助金额:
$ 0.16万 - 项目类别: